MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Puma Biotechnology Net Debt 2011-2026 | PBYI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Puma Biotechnology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -42 M | -14.1 M | 26.2 M | 37.5 M | 1.83 M | 86.5 M | 100 M | -33.2 M | -194 M | -31.6 M | -38.5 M | -43 M | -137 M | -53.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 100 M | -194 M | -23.9 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLineRx Ltd.
BLRX
|
-13.9 M | $ 2.25 | 1.81 % | $ 908 M |  Israel |
 |
BioNTech SE
BNTX
|
-973 M | $ 91.28 | 0.11 % | $ 27.2 B |  Germany |
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 330.34 | 3.6 % | $ 43.3 B |  USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-5.64 M | $ 0.44 | -16.64 % | $ 5.04 M | Israel |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | France |
 |
Catalyst Pharmaceuticals
CPRX
|
-706 M | $ 24.98 | 1.17 % | $ 3.05 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
263 K | $ 10.14 | -0.29 % | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
-16.6 M | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
-3.44 M | $ 0.53 | -3.07 % | $ 6.98 M | USA |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-53 M | $ 37.7 | 1.26 % | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-141 M | $ 49.15 | -0.73 % | $ 4.42 B |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-22.2 M | $ 2.96 | -1.0 % | $ 252 M | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
CytomX Therapeutics
CTMX
|
-28.7 M | $ 4.4 | -3.51 % | $ 607 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Citius Pharmaceuticals
CTXR
|
-2.99 M | $ 0.86 | 0.67 % | $ 5.79 M | USA |
 |
Cue Biopharma
CUE
|
-22.9 M | $ 0.18 | -1.61 % | $ 17.1 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-51.1 M | $ 4.15 | -32.52 % | $ 10.4 M | USA |
 |
Daré Bioscience
DARE
|
-23.5 M | $ 1.81 | 4.02 % | $ 20.2 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-188 M | $ 20.36 | -3.32 % | $ 2.84 B | France |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-206 M | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Denali Therapeutics
DNLI
|
-158 M | $ 19.38 | -6.15 % | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
-6.38 M | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-26.5 M | $ 31.37 | 1.0 % | $ 2.08 B | USA |
 |
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | USA |